Retatrutide: The Triple-Threat Obesity Drug Redefining Weight Loss Medicine
Leading the charge is retatrutide, a next-generation obesity drug developed by Eli Lilly that’s generating unprecedented excitement. Dubbed the “triple agonist,”…
Category: Research Insights
Weight Loss Market Outlook 2030: Growth Drivers & Key Segments
The $1.5 Trillion Weight Loss Economy of 2030: A Breakdown of the Market Reshaping Health By 2030, the global weight…
Next Up in Obesity Drugs: A Timeline of What’s Coming to Market (2026–2028+)
The fight against obesity is entering an exciting new era. With blockbuster drugs like Wegovy (semaglutide) and Zepbound (tirzepatide) already…
Myostatin’s Role in the Next Weight-Loss Revolution
Key Points Background Current weight-loss methods, including lifestyle changes, surgery, and drugs like Wegovy and Zepbound, often result in both…
10 Drugs Related to Obesity
Obesity is a growing global health concern, with medications playing a crucial role in its management. Some drugs aid in…
Orforglipron: The Oral Alternative to Injection-Based Weight Loss and Diabetes Drugs
Key Highlights: A New Hope for Obesity and Diabetes Obesity and type 2 diabetes (T2D) are global health crises, affecting 1…
10 Eye-Opening Facts About Obesity in 2025
Projected 1 Billion Obese by 2025 (WHO) Childhood Obesity Doubles to 390 Million (2020–2025) U.S. Adult Obesity at 40.3% (2023)…